ERBB2 and breast cancer: Therefore, Cx43 was significantly down-regulated in virtually all of the highly aggressive breast cancer subtypes (TNBC and ER− PR− HER2+), comprising two-thirds of the total tested samples, and 60% of the less aggressive subtype.